Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Lilia Stefaniwsky

Gastroenterology Palm Harbor, FL Medical Doctor

NPI 1053765206 CMS profile 8790255

33920 US 19 N Ste 124, Palm Harbor, FL 34684

Open in the dashboard

General payments

$5,662

270 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lilia Stefaniwsky of Palm Harbor, FL is reported in the CMS Open Payments database as having received $5,662 across 270 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,836 79
2024 General $1,237 53
2023 General $1,464 83
2022 General $451 22
2021 General $438 22
2020 General $237 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lilia Stefaniwsky
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Lilia Stefaniwsky were reported at $1,836. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Lilia Stefaniwsky Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $237 $224 $74–$624 $114
2021 $438 $352 $106–$1,054 $132
2022 $451 $448 $129–$1,270 $149
2023 $1,464 $533 $150–$1,390 $160
2024 $1,237 $605 $160–$1,606 $164
2025 $1,836 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $2,044 98 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $522 30 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $502 28 payments
  4. Celgene Corporation $390 28 payments
  5. Janssen Biotech, Inc. $337 13 payments
  6. Genzyme Corporation $289 12 payments
  7. Pfizer Inc. $255 12 payments
  8. Gilead Sciences, Inc. $180 6 payments
  9. Regeneron Healthcare Solutions, Inc. $147 7 payments
  10. Zimmer Biomet Holdings, Inc. $135 1 payment
  11. Other $862 35 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $5,549 268 payments
  2. Education $114 2 payments
Products named General payments · program years 2020–2025
  1. RINVOQ $857 43 payments
  2. LINZESS $610 28 payments
  3. SKYRIZI Immunology $526 31 payments
  4. ZEPOSIA $491 28 payments
  5. ENTYVIO $468 26 payments
  6. XIFAXAN $466 23 payments
  7. SKYRIZI Immunology $456 23 payments
  8. CREON $420 20 payments
  9. STELARA $291 11 payments
  10. DUPIXENT $260 11 payments
  11. Other $2,086 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

589

Median for Gastroenterology: 569

Drug cost

$81,961

Median for Gastroenterology: $104,976

Branded share of claims

27.2%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 32 $29,747
Movantik Naloxegol Oxalate Brand 22 $14,530
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 75 $12,800
Trulance Plecanatide Brand 11 $8,019
Colestipol Hcl Generic 46 $3,865
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 20 $3,243
Pantoprazole Sodium Generic 135 $1,814
Esomeprazole Magnesium Generic 23 $1,578
Omeprazole Generic 81 $1,488
Sucralfate Generic 23 $1,218

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$66,427

Medicare's payments for the services billed

Medicare patients

294

Average age 75

Services billed

683

216 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 38%
Depression 36%
Chronic kidney disease 32%
Diabetes 27%
Atrial fibrillation 27%
Osteoporosis 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $181
$181 — —
CREON
  • AbbVie, Inc. $151
$151 — —
SKYRIZI
  • AbbVie, Inc. $151
$151 — —
STELARA
  • Janssen Biotech, Inc. $124
$124 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $68
  • GENZYME CORPORATION $43
$111 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

270 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record